ENFUVIRTIDE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12457443 | https://www.ncbi.nlm.nih.gov/pubmed/30836922 | https://www.ncbi.nlm.nih.gov/pubmed/30000878 | https://www.drugbank.ca/drugs/DB00109 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021481s032lbl.pdf

Enfuvirtide is a linear 36-amino acid synthetic peptide that inhibits the fusion of HIV-1 with CD4 cells. Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed. Common adverse drug reactions associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: https://www.drugs.com/pro/FUZEON.html	Primary		Approved 8583	FUZEON Approved Use FUZEON is an HIV-1 fusion inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment experienced patients with HIV-1 replication despite ongoing antiretroviral therapy. Launch Date 2003

PubMed

Title	Date	PubMed
Inhibiting HIV-1 entry with fusion inhibitors.	2003-09	12871113
Virus entry as a target for anti-HIV intervention.	2003-09	12871111
[HIV infections: further options for combination therapy].	2003-07-11	12899165
First fusion inhibitor for advanced HIV.	2003-07	12877130
Large-scale manufacture of peptide therapeutics by chemical synthesis.	2003-07	12815383
Enfuvirtide (Fuzeon) for HIV Infection.	2003-06-23	12817195
[First fusion inhibitor is available. No entry for HIV-1 viruses].	2003-06-19	12891854
New class of medications approved for advance HIV.	2003-06-10	12793380
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.	2003-06-01	12794544
FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.	2003-06	12866478
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.	2003-06	12861974
Gateways to clinical trials.	2003-06	12851663
Fusion inhibition--a major but costly step forward in the treatment of HIV-1.	2003-05-29	12773653
Novel therapies based on mechanisms of HIV-1 cell entry.	2003-05-29	12773651
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.	2003-05-29	12773645
HIV infection--a new drug and new costs.	2003-05-29	12773643
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.	2003-05-29	12637625
Enfuvirtide, a new drug for HIV infection.	2003-05-10	12747873
[HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].	2003-05-09	12774800
Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants.	2003-05-02	12700461
Fusion inhibitor approved.	2003-05	12816619
Drug profile: enfuvirtide (Fuzeon, ENF, T-20).	2003-05	12809104
The optimal use of enfuvirtide.	2003-05	12809103
Enfuvirtide access, administration, and patient education.	2003-05	12809102
Enfuvirtide.	2003-05	12755128
FDA news. Price criticized for new anti-HIV drug.	2003-05	12751460
Enfuvirtide approved for defusing HIV.	2003-05	12726955
US FDA approves new class of HIV therapeutics.	2003-05	12721558
Drug cost. States concerned about Fuzeon.	2003-04-11	12728848
ConFuzeon reigns.	2003-04	12751446
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.	2003-04	12741628
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20.	2003-04	12736375
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.	2003-03-28	12646792
T-20: most expensive AIDS drug ever at $25,000 per year?	2003-03-14	12712938
Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003-03	12765161
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003-03	12765160
New classes of HIV drugs on the horizon. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003-03	12765159
Gateways to clinical trials. March 2003.	2003-03	12731460
FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?	2003-03	12728858
Fuzeon data review.	2003-03	12728857
Long path to approval. A look back at the road to Fuzeon.	2003-03	12728856
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.	2003-03	12689409
New antiretroviral drugs.	2003-03	12667250
Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.	2003-02	12562683
Projecting future drug expenditures--2003.	2003-01-15	12561658
Anti-HIV drug updates--three drugs on the near horizon.	2003-01	12647672
Five new drugs enter the homestretch.	2002-12	12635598
New drugs show promise in attacking HIV.	2002-12	12572158
HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.	2002-09-06	12765126
[T-20: a fusion inhibitor].	2002	12703471

Sample Use Guides

In Vivo Use Guide

Adults: Recommended dosage of Enfuvirtide is 90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh, or abdomen. Pediatric Patients (weighing at least 11kg): Recommended dose of 2 mg/kg twice daily up to a maximum dose of 90 mg twice daily injected subcutaneously.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Wed Apr 02 07:44:56 GMT 2025` Edited by `admin` on `Wed Apr 02 07:44:56 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	19OWO1T3ZE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENFUVIRTIDE

Official Name

English

FUZEON

Preferred Name

English

ENFUVIRTIDE [VANDF]

Common Name

English

DP-178

Code

English

T-20

Code

English

DP178

Code

English

enfuvirtide [INN]

Common Name

English

ENFUVIRTIDE [EMA EPAR]

Common Name

English

ENFUVIRTIDE [USAN]

Common Name

English

Enfuvirtide [WHO-DD]

Common Name

English

T20

Code

English

ENFUVIRTIDE [MART.]

Common Name

English

ENFUVIRTIDE [MI]

Common Name

English

ENFUVIRTIDE [ORANGE BOOK]

Common Name

English

ENFUVIRTIDE [HSDB]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175616